Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …

Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save

Comments

Comments are disabled for this post.